Cargando…

Incretin Effect of Glucagon-Like Peptide 1 Receptor Agonist Is Preserved in Presence of ABCC8/SUR1 Mutation in β-Cell

Detalles Bibliográficos
Autores principales:	Bourron, Olivier, Chebbi, Fatma, Halbron, Marine, Saint-Martin, Cécile, Bellanné-Chantelot, Christine, Abed, Ahmed, Charbit, Beny, Magnan, Christophe, Lacorte, J.M., Hartemann, Agnès
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2012
Materias:	Online Letters: Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3476900/ https://www.ncbi.nlm.nih.gov/pubmed/23093687 http://dx.doi.org/10.2337/dc12-0535

Ejemplares similares

Association of Type B Insulin Resistance and Type 1 Diabetes Resulting in Ketoacidosis
por: Bourron, Olivier, et al.
Publicado: (2012)

Glucagon-like peptide 1 and dysglycemia: Conflict in incretin science
por: Singh, Awadhesh Kumar
Publicado: (2015)

Promoter DNA Methylation Regulates Murine SUR1 (Abcc8) and SUR2 (Abcc9) Expression in HL-1 Cardiomyocytes
por: Fatima, Naheed, et al.
Publicado: (2012)

Pancreatitis Associated With Incretin-Based Therapies
por: Iyer, Shridhar N., et al.
Publicado: (2013)

Glucocorticoid-Induced Hyperinsulinism in a Preterm Neonate with Inherited ABCC8 Variant
por: Motte-Signoret, Emmanuelle, et al.
Publicado: (2022)

Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
por: Capozzi, Megan E, et al.
Publicado: (2018)

The incretin/glucagon system as a target for pharmacotherapy of obesity
por: Del Prato, Stefano, et al.
Publicado: (2021)

Correction: Inactive matrix gla protein plasma levels are associated with peripheral neuropathy in Type 2 diabetes
por: Jeannin, Anne-Caroline, et al.
Publicado: (2020)

Inactive matrix gla protein plasma levels are associated with peripheral neuropathy in Type 2 diabetes
por: Jeannin, Anne-Caroline, et al.
Publicado: (2020)

Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1: Incretin actions beyond the pancreas
por: Seino, Yutaka, et al.
Publicado: (2013)

The Links of Ghrelin to Incretins, Insulin, Glucagon, and Leptin After Bariatric Surgery
por: Skuratovskaia, Daria, et al.
Publicado: (2021)

Serum concentration and vascular expression of adiponectin are differentially associated with the diabetic calcifying peripheral arteriopathy
por: Aubert, Carole E., et al.
Publicado: (2019)

Degradation of the Incretin Hormone Glucagon-Like Peptide-1 (GLP-1) by Enterococcus faecalis Metalloprotease GelE
por: LeValley, Stephanie L., et al.
Publicado: (2020)

Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies
por: Shaefer, Charles F.
Publicado: (2016)

Incretin concept revised: The origin of the insulinotropic function of glucagon‐like peptide‐1 – the gut, the islets or both?
por: Yabe, Daisuke, et al.
Publicado: (2017)

Observations sur la cataracte
por: Monnot, A., et al.
Publicado: (1802)

Effects of glucagon-like peptide-1 receptor agonists on glucose excursion and inflammation in overweight or obese type 2 diabetic patients
por: Huang, Xiao-Min, et al.
Publicado: (2023)

Pregnancy in Women With Monogenic Diabetes due to Pathogenic Variants of the Glucokinase Gene: Lessons and Challenges
por: Timsit, José, et al.
Publicado: (2022)

Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young
por: Ellard, S., et al.
Publicado: (2008)

Acylation of the Incretin Peptide Exendin-4 Directly Impacts Glucagon-Like Peptide-1 Receptor Signaling and Trafficking
por: Lucey, Maria, et al.
Publicado: (2021)

Relevance of Autophagy Induction by Gastrointestinal Hormones: Focus on the Incretin-Based Drug Target and Glucagon
por: Kanasaki, Keizo, et al.
Publicado: (2019)

The Change in Glucagon Following Meal Ingestion Is Associated with Glycemic Control, but Not with Incretin, in People with Diabetes
por: Yoo, Soyeon, et al.
Publicado: (2021)

Targeting SUR1/Abcc8-Type Neuroendocrine K(ATP) Channels in Pancreatic Islet Cells
por: Nakamura, Yumiko, et al.
Publicado: (2014)

Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination—are we exploiting their full potential in a real life setting?
por: Cigrovski Berkovic, Maja, et al.
Publicado: (2020)

Diabetes Mellitus, Extreme Insulin Resistance, and Hypothalamic-Pituitary Langerhans Cells Histiocytosis
por: Sollier, Mathilde, et al.
Publicado: (2019)

Enteral supplementation with glutamine, fiber, and oligosaccharide modulates incretin and glucagon-like peptide-2 secretion
por: Joo, Erina, et al.
Publicado: (2015)

Update of variants identified in the pancreatic β‐cell K(ATP) channel genes KCNJ11 and ABCC8 in individuals with congenital hyperinsulinism and diabetes
por: De Franco, Elisa, et al.
Publicado: (2020)

Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus
por: Rauch, Thomas, et al.
Publicado: (2012)

Autophagy deficiency in β cells blunts incretin-induced suppression of glucagon release from α cells
por: Kim, Min Joo, et al.
Publicado: (2016)

Artificial Sweeteners Have No Effect on Gastric Emptying, Glucagon-Like Peptide-1, or Glycemia After Oral Glucose in Healthy Humans
por: Wu, Tongzhi, et al.
Publicado: (2013)

Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease
por: Yamaoka-Tojo, Minako, et al.
Publicado: (2010)

The incretin hormone glucagon‐like peptide 1 increases mitral cell excitability by decreasing conductance of a voltage‐dependent potassium channel
por: Thiebaud, Nicolas, et al.
Publicado: (2016)

Clinicopathological Impact of ABCC1/MRP1 and ABCC4/MRP4 in Epithelial Ovarian Carcinoma
por: Bagnoli, Marina, et al.
Publicado: (2013)

Roles of ABCC1 and ABCC4 in Proliferation and Migration of Breast Cancer Cell Lines
por: Low, Floren G., et al.
Publicado: (2020)

The Incretins and Pancreatic β-Cells: Use of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide to Cure Type 2 Diabetes Mellitus
por: Kim, Mi-Hyun, et al.
Publicado: (2010)

A silica-based pH-sensitive nanomatrix system improves the oral absorption and efficacy of incretin hormone glucagon-like peptide-1
por: Qu, Wei, et al.
Publicado: (2012)

Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors
por: Nauck, M.
Publicado: (2016)

Neonatal Diabetes and Congenital Hyperinsulinism Caused by Mutations in ABCC8/SUR1 are Associated with Altered and Opposite Affinities for ATP and ADP
por: Ortiz, David, et al.
Publicado: (2015)

Sitagliptin Improves Postprandial Hyperglycemia by Inhibiting Glucagon Secretion in Werner Syndrome With Diabetes
por: Watanabe, Kaneyuki, et al.
Publicado: (2013)

Type 1 Diabetes in People Hospitalized for COVID-19: New Insights From the CORONADO Study
por: Wargny, Matthieu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s9q3o1ilojsqs3kecdspuq4693